Tabrecta and Flatulence - a phase IV clinical study of FDA data

Summary:

Flatulence is reported as a side effect among people who take Tabrecta (capmatinib hydrochloride), especially for people who are female, 60+ old, also take Losartan, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Flatulence when taking Tabrecta. It is created by eHealthMe based on reports of 2,093 people who have side effects when taking Tabrecta from the FDA, and is updated regularly.

What is Tabrecta?

Tabrecta has active ingredients of capmatinib hydrochloride. eHealthMe is studying from 2,095 Tabrecta users. Check the latest studies of Tabrecta.

What is Flatulence?

Flatulence (flatus expelled through the anus) is found to be associated with 1,810 drugs and 1,881 conditions by eHealthMe. Check the latest studies of Flatulence.

On Aug, 29, 2025

2,093 people reported to have side effects when taking Tabrecta.
Among them, 15 people (0.72%) have Flatulence.

Among these 15 people:

What is the gender of people who have Flatulence when taking Tabrecta? *

female: 66.67 %
male: 33.33 %

What is the age of people who have Flatulence when taking Tabrecta? *

What are other drugs people take besides Tabrecta? *

Metformin: 1 person, 6.67%
Losartan: 1 person, 6.67%

What are other side effects people have besides Flatulence? *

Peripheral Swelling: 12 people, 80.00%
Fatigue (feeling of tiredness): 8 people, 53.33%
Muscle Spasms (muscle contraction): 7 people, 46.67%
Abdominal Distension: 6 people, 40.00%
Dyspnea (difficult or laboured breathing): 5 people, 33.33%
Joint Swelling: 5 people, 33.33%
Nausea (feeling of having an urge to vomit): 5 people, 33.33%
Insomnia (sleeplessness): 4 people, 26.67%
Hypersensitivity: 4 people, 26.67%
Pleural Effusion (water on the lungs): 4 people, 26.67%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 4 people, 26.67%
Lung Cancer Metastatic (lung cancer spreads to other parts): 2 people, 13.33%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 13.33%
Rashes (redness): 1 person, 6.67%
Lung Carcinoma Cell Type Unspecified Stage 0 (the lung cancer has not spread beyond the inner lining of the lung): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Tabrecta and have Flatulence?

- Check whether Flatulence is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tabrecta:

Tabrecta (2,095 reports)

Flatulence treatments and more:

Flatulence (70,665 reports)

Browse all side effects of Tabrecta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Flatulence:

Flatulence (1,810 drugs)

Browse all the conditions that are associated with Flatulence:

Flatulence (1,881 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on capmatinib hydrochloride (the active ingredients of Tabrecta) and Tabrecta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.